Radiation-Guided Nanoparticles Enhance PARP Inhibitor Efficacy in Metastatic Tumors

Researchers from Tel Aviv University have developed radiation-guided nanoparticles that enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors. The research, published in the Journal of Controlled Release, demonstrates the potential of this treatment approach in overcoming immune evasion and improving tumor targeting. The study involved a combination of traditional 2-dimensional cell cultures, advanced 3-dimensional spheroids, tumor-on-a-chip platforms, and in vivo models to evaluate the efficacy of the radiation-guided nanoparticles.

Key Takeaways:

• The study highlights the potential of radiation-guided nanoparticles to enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors.
• The researchers developed P-selectin-targeted poly (lactic-co-glycolic) acid (PLGA)-poly (ethylene glycol) (PEG)-based nanoparticles (NPs) encapsulating PARP and PD-L1 inhibitors at a synergistic ratio.
• The nanoparticles showed improved accumulation and efficacy in primary and brain-metastatic BRCA1-deficient tumors via immunotherapy.
• The research involved a combination of traditional 2-dimensional cell cultures, advanced 3-dimensional spheroids, tumor-on-a-chip platforms, and in vivo models to evaluate the efficacy of the radiation-guided nanoparticles.
• The study demonstrates the potential of this treatment approach in overcoming immune evasion and improving tumor targeting.
• The researchers used a combination of PARP and PD-L1 inhibitors to target BRCA1-deficient cancer cells and their associated angiogenic endothelial cells.

Statistics:

• The study demonstrated a 30% increase in programmed cell death protein-1 ligand (PD-L1) expression in BRCA1-deficient cancer cells after treatment with the PARPi, niraparib.
• The radiation-guided nanoparticles showed a 25% increase in accumulation in primary tumors compared to non-targeted nanoparticles.
• The study involved 10 different in vivo models to evaluate the efficacy of the radiation-guided nanoparticles in primary and metastatic BRCA1-deficient tumors.
• The research demonstrated a 50% reduction in tumor volume in mice treated with the radiation-guided nanoparticles compared to controls.

Sources:

• Journal of Controlled Release, 2025:113812. Journal of Controlled Release can be contacted at: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
• Giuseppe Longobardi, Dept. of Physiology and Pharmacology, Faculty of Medical and Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
• Research article: Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via Immunotherapy.